Montagnier L
Arch Inst Pasteur Tunis. 1981 Sep-Dec;58(3):297-312.
After briefly reviewing recent advances in the knowledge of various molecular species of interferon, some prospects of the basic research in this field are discussed: 1) interferon as a physiological hormone endowed with antiviral and immunomodulatory functions and possibly interacting with the neuroendocrine system; 2) interferon as an inducible protein, a model which allows a refined molecular analysis using the probes made available by cloning; 3) the various mechanisms of interferon action at the biochemical level. In the last section, the past and future of interferon as a therapeutic agent are examined. For its therapeutic evaluation, interferon needs to be compared with the best chemotherapeutic agents now available against viruses and tumors. Large scale clinical trials require a large production of interferons. Hence, a dilemma will be encountered: either pursue trials with natural preparations which are always a mixture of several types and subclasses of interferons in no defined proportions; wait for availability of the interferons produced by genetic recombinants which are cloned species, and try these various species, each one alone and in combination, or even more use hybrid molecular species. The availability of accurate markers for the action of interferon in man will be of great usefulness to study its therapeutic action and furthermore to define its indications. Finally, the possibility is raised that some non toxic interferon inducers, such as Poly A, Poly U, could also be used as well as interferon itself.
在简要回顾了干扰素各种分子类型知识的近期进展之后，讨论了该领域基础研究的一些前景：1）干扰素作为一种具有抗病毒和免疫调节功能且可能与神经内分泌系统相互作用的生理激素；2）干扰素作为一种诱导蛋白，是一种利用克隆提供的探针进行精细分子分析的模型；3）干扰素在生化水平上的各种作用机制。在最后一部分，考察了干扰素作为治疗剂的过去和未来。为了对其进行治疗评估，需要将干扰素与目前对抗病毒和肿瘤的最佳化学治疗剂进行比较。大规模临床试验需要大量生产干扰素。因此，将面临一个两难境地：要么使用天然制剂进行试验，而天然制剂总是几种类型和亚类干扰素的混合物，比例不明确；要么等待基因重组产生的干扰素，这些是克隆的种类，然后单独或联合试验这些不同的种类，甚至更多地使用杂交分子种类。准确的人体干扰素作用标志物的可用性对于研究其治疗作用以及进一步确定其适应症将非常有用。最后，提出了一些无毒的干扰素诱导剂，如聚A、聚U，也可以与干扰素本身一起使用的可能性。
